Pioneers in Neuroscience

A Letter from Alphonse Galdes, Ph.D., Head of Pharmaceutical Operations and Technology at Biogen: It’s Time for Companies to Act Like the Climate Crisis is a Health Crisis
Dominic Walsh | Decoding the pathology of Alzheimer’s 

Since amyloid beta and tau were first discovered more than 100 years ago, scientists have been trying to understand their role in Alzheimer’s disease and how modulating genetic risk factors for developing Alzheimer’s can address the disease. Hear from Dominic Walsh, head of Biogen’s Neurodegeneration Research Unit.

The future of medicine | A conversation with Alfred Sandrock

Biogen’s Executive Vice President, Research and Development, Alfred ‘Al’ Sandrock, M.D., Ph.D., on how our growing understanding of genetics coupled with the use of biomarkers and measurement tools will provide us with insights that could potentially revolutionize the field of medicine and drug development.

Amyotrophic Lateral Sclerosis (ALS) at Biogen

We aspire to improve the lives of people living with and caring for those with ALS.

Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
Biogen Digital Health

Biogen Digital Health aspires to transform patients’ lives and Biogen by making personalized & digital medicine in neuroscience a reality.

SOD1-ALS: Tofersen Early Access Program (EAP)
Healthy Climate, Healthy Lives™

Biogen marks one-year anniversary of $250 million, 20-year commitment to accelerate action on the greatest challenges of our time: climate, health and equity.

U.S. FDA approves ADUHELM™ (aducanumab-avwa) for Alzheimer’s disease

Biogen and Eisai receive FDA accelerated approval for a new therapy targeting amyloid beta plaque.

11/22/21 11:00 AM EST
Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease
View all news
Biogen updates delivered to your inbox
Diversity, Equity and Inclusion

Biogen is committed to the power of diversity – in our organization and among our patients and customers. Diversity is an essential asset of complementary strengths and perspectives from which all benefit, and which must unite us, not divide us.

Where Science Meets Humanity

Science that transforms patient lives. Science that seeks to solve societal problems. Science that acts with purpose. Science that is inspired by the diversity and passion of our people. Discover where science meets humanity at Biogen.

Follow us on social media